Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Alzecure Pharma: Initiates Phase I “MAD” Study

2021-10-04

16:09

FT

Fredrik Thor

Redeye maintain our view of Alzecure and Alzheimer’s candidate ACD856, a part of the company's Neurorestore platform, following today’s announcement that the first person has been dosed in the MAD (“Multiple Ascending Dose”) phase I study. We are encouraged that the project is progressing and that the timeline is kept (expected readout H1 2022) and look forward to the results.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers